Journal of occupational and environmental medicine · 2025
Evaluation of Sphingolipid Metabolism in Silicosis Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aksu Kaplan Neslihan, Reçber Tuba, Sarı Suat, Kartal Yasemin, Cenk Muharrem, Öz Esin, Nemutlu Emirhan, Öztaş Yeşim, Öztiş Türkan Nadir, Sabuncuoğlu Suna
Аннотация
OBJECTIVE: Silicosis is a fibrotic lung disease caused by the inhalation of crystalline silica. This study investigates sphingolipid metabolism in silicosis patients using plasma samples.
METHODS: GC-MS-based untargeted metabolomics identified alterations in the sphingolipid pathway, while LC-MS targeted specific ceramide and sphingomyelin species. Enzyme activities of acid ceramidase, neutral sphingomyelinase, sphingosine kinase-1, and sphingosine-1-phosphate lyase-1 were also assessed.
RESULTS: Results showed elevated sphingolipid levels and reduced enzyme activities in patients versus controls. In silico molecular docking suggested interactions between SiO 2 and pathway enzymes. Metabolomic analysis revealed disrupted sphingolipid and fatty acid pathways.
CONCLUSIONS: These findings highlight the role of sphingolipid dysregulation in silicosis pathogenesis and suggest its potential as a biomarker and therapeutic target. Understanding these mechanisms could improve management and treatment strategies for this debilitating disease.
METHODS: GC-MS-based untargeted metabolomics identified alterations in the sphingolipid pathway, while LC-MS targeted specific ceramide and sphingomyelin species. Enzyme activities of acid ceramidase, neutral sphingomyelinase, sphingosine kinase-1, and sphingosine-1-phosphate lyase-1 were also assessed.
RESULTS: Results showed elevated sphingolipid levels and reduced enzyme activities in patients versus controls. In silico molecular docking suggested interactions between SiO 2 and pathway enzymes. Metabolomic analysis revealed disrupted sphingolipid and fatty acid pathways.
CONCLUSIONS: These findings highlight the role of sphingolipid dysregulation in silicosis pathogenesis and suggest its potential as a biomarker and therapeutic target. Understanding these mechanisms could improve management and treatment strategies for this debilitating disease.